The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Radiotheranostics Market Increase Between 2026 And 2030?
The radiotheranostics market size has experienced rapid growth in recent years. It is projected to increase from $10.05 billion in 2025 to $11.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. The expansion witnessed in the historic period is attributable to the increasing use of nuclear medicine diagnostics, the expansion of oncology-focused clinical research, the availability of therapeutic radioisotopes, the rising adoption of PET and SPECT imaging, and growing collaboration between pharma and imaging providers.
The radiotheranostics market is projected for substantial expansion in the coming years, with its size anticipated to reach $19.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.9%. This projected growth can be attributed to several factors, including the increasing approvals of radiotheranostic drugs, rising investments in precision oncology, the expansion of isotope production infrastructure, a growing demand for personalized cancer care, and the increasing integration of AI in treatment selection. During the forecast period, major trends are expected to involve the increasing adoption of targeted radioligand therapies, the rising use of paired diagnostic and therapeutic isotopes, the growing integration of precision imaging and therapy, the expansion of personalized oncology applications, and an enhanced focus on molecular-level cancer targeting.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12270&type=smp
What Primary Factors Are Fueling The Expansion Of The Radiotheranostics Market?
The expanding occurrence of cancer is projected to drive the future expansion of the radiotheranostics market. Cancer is defined as a disease where certain body cells multiply without control and disseminate to other parts of the body. In cancer treatment, radiotheranostics medications are frequently utilized to provide the pinnacle of personalized medicine. This is achieved through the application of combined diagnostic and therapeutic radionuclide probes that enable the targeted identification and treatment of specific cells, predominantly cancerous ones. These probes are tailored to the patient’s specific health status, thereby improving treatment effectiveness and clinical outcomes. As an illustration, data from January 2024, provided by the American Cancer Society, a US-based nonprofit cancer advocacy organization, indicated that cancer cases rose to 2,001,140 from 1,958,310 in 2023, marking a 2.19% increase. Consequently, the rising incidence of cancer fuels demand in the radiotheranostics market.
What Are The Core Segment Classifications In The Radiotheranostics Market?
The radiotheranostics market covered in this report is segmented –
1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes
2) By Approach: Targeted Therapeutic, Targeted Diagnostic
3) By Application: Oncology, Non-Oncology
4) By End-Users: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Technetium-99: Technetium-99m, Technetium-99 Pertechnetate
2) By Gallium-68: Gallium-68 DOTATATE, Gallium-68 PSMA
3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment, Iodine-131 For Hyperthyroidism Treatment
4) By Iodine-123: Iodine-123 For Thyroid Scans, Iodine-123 For Cardiac Imaging
5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging, FDG For Brain Imaging
6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer, Yttrium-90 For Radioimmunotherapy
7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer, Lutetium-177 DOTATATE For Neuroendocrine Tumors
8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy, Copper-67 In Clinical Trials
9) By Copper (Cu) 64: Copper-64 For PET Imaging, Copper-64 For Radiotherapy
10) By Other Radioisotopes: Radium-223, Samarium-153, Other Emerging Radioisotopes In Theranostics
Which Trends Are Expected To Shape The Radiotheranostics Market?
Leading companies in the radiosurgery and radiotherapy robotics market are concentrating on implementing advanced technological solutions, such as dynamic surface positioning and monitoring systems, to maintain their competitive edge. This system functions as a patient tracking tool for surface-guided radiation therapy (SGRT), utilizing a thermal-surface camera to observe patient position and detect any movement during treatment. For instance, in May 2023, Brainlab, a Germany-based software and hardware developer specializing in radiotherapy and radiosurgery, launched its ExacTrac Dynamic Surface Positioning and Monitoring System. This singular camera unit solution is designed to ensure uniformity across the radiation department and enable continuous patient surveillance during breath-hold treatments. The primary goal of ExacTrac Dynamic Surface is to establish consistency throughout the department and provide accurate tracking. Clinicians will find a short learning curve with ExacTrac Dynamic Surface on any linac, attributed to its single, intuitive interface and standardized workflows.
Who Are The Leading Firms Participating In The Radiotheranostics Market?
Major companies operating in the radiotheranostics market are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.
Access The Complete Radiotheranostics Market Report:
https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report
Which Region Leads The Radiotheranostics Market By Size?
North America was the largest region in the radiotheranostics market in 2025. The regions covered in the radiotheranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Radiotheranostics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12270&type=smp
Browse Through More Reports Similar to the Global Radiotheranostics Market 2026, By The Business Research Company
Radiotherapy Devices Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/radiotherapy-devices-global-market-report
Veterinary Stereotactic Radiosurgery System Global Market Report 2026
Image Guided Radiation Therapy Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
